The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Https://uk.yahoo.com/news/next-pandemic-likely-caused-flu-085221498.html
If the vibes are positive and we get a quick acquisition within the next few months and its a good company with good margins then i would hold most of my shares. I have around 210,000 shares. Remember £130M+ cash is huge for a AIM company
I think with £130M in the bank , there is so much potential to acquire 2 or 3 companies that will generate an annual revenue of £100M+ and form Novacyt into a multi billion pound organisation . This company could well be £25+ per share in the next few years.
Shush, I know what you saying , but its all about how LR sells the story and what promises he can make to convince the Institutional Investors. If they see real rewards and there is a clear solid business strategy , then yes , they will come on board.
With LR as CEO , he will attract institutional investors on board, and that will stabilise the SP volatility , and steady raise . With more acquisitions from the money received from DHSC , this would create increase revenue, this will only grow the company into a billion pound organisation.
I agree I really think yesterday's RNS was worded by LR and it was very much AIM focused to create positive sentiment. We have not seen that type of RNS fashioned since Graham Mullis was targeting his LTIP in 2020
Can we start speculating with which companies Novacyt could / should go after ? . What can £130M buy these days ? Ideally Novacyt should be going for companies with real potential for profit margins of £25+M / year
I am hoping and with LR contacts we expect institutional investors come to Novacyt ., once Novacyt have won the case . This is where LR is the key in being the CEO and his presentation skills convincing Institutional investors to invest , which in turn will stabilize the share price and bring share holder value .
The DHSC will pay up in full . This case with Novacyt will not be reported in national news . Its no big deal in grand scheme of things with the national and international news . Wars are occurring and immigration issues nationally are more of a concern to public now than dispute with government over covid-19 diagnostic test payments . So in my opinion the government will pay up full to Novacyt . Its the tax payers that will pay for all this government's legal administration .
this means Novacyt are cash rich = £130M +
We still have around 7 weeks to go before court case . A steady raise every day / weekly from now , should get to £2-4 by the court case . I still think this will go to court as Novacyt mean intent in getting their £81.5 M + interest + clear their good name
Handy111 , first stage is to recoup all my money £710K . anything more is just luck . I just want to recoup my money back . Its a lot of money , hard lesson for me to learn this , not to ever invest so much again !
Gizmo , is this what you are talking about.
https://www.fiercebiotech.com/medtech/pacbio-plots-budget-cuts-after-dna-sequencing-revenue-shortfalls
Looking at the turnover over of Pacbio , it gives me great encouragement that Yourgene can bring in huge revenues and create shareholder value.
Lets recap with the RNS made on 16th June 2022 by Novacyt
On 15 June 2022, the Company filed a defence of the claim received on 25 April 2022 and a counterclaim of £81.5m against the DHSC. The value of the counterclaim is broadly in line with the amounts previously announced by the Company in its full year 2020 results, plus related interest. The Company continues to believe it has strong grounds to defend the claim and assert its contractual rights, including recovering outstanding sums due from the DHSC under the counterclaim.'
Can this statement be taken also to mean also reputational damages and loss of earnings incurred ?
https://www.lse.co.uk/rns/NCYT/dhsc-dispute-update-ldcfhiyo5p85qx6.html